To determine whether nNOS blockade enhanced the anti-melanoma activity of immune checkpoint inhibitors, we used an immunocompetent murine allograft tumor melanoma model, which has been used in preclinical studies and shown to be responsive to immunotherapy, mimicking patient responses [31,60]. This evidence concerns the gene NOS1 and melanoma.